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Abstract
Melanoma antigen gene protein-A11 (MAGE-11) of the MAGE family of cancer-germline antigens
increases androgen receptor (AR) transcriptional activity through its interaction with the AR NH2-
terminal FXXLF motif. The present study investigated the regulatory mechanisms that control
MAGE-11 expression during androgen deprivation therapy and prostate cancer progression. Studies
include the CWR22 xenograft model of human prostate cancer, clinical specimens of benign and
malignant prostate, and prostate cancer cell lines. MAGE-11 mRNA levels increased 100 to 1500
fold during androgen deprivation therapy and prostate cancer progression, with highest levels in the
castration-recurrent CWR22 xenograft and clinical specimens of castration-recurrent prostate cancer.
Pyrosequencing of genomic DNA from prostate cancer specimens and cell lines indicated the
increase in MAGE-11 resulted from DNA hypomethylation of a CpG island in the 5´ promoter of
the MAGE-11 gene. Sodium bisulfite sequencing of genomic DNA from benign and malignant
prostate tumors and prostate cancer cell lines revealed DNA hypomethylation at individual CpG sites
at the transcription start site were most critical for MAGE-11 expression. Cyclic AMP also increased
MAGE-11 expression and AR transcriptional activity in prostate cancer cell lines. However, cyclic
AMP did not alter DNA methylation of the promoter and its effects were inhibited by extensive DNA
methylation in the MAGE-11 promoter region. Increased expression of the AR coregulator
MAGE-11 through promoter DNA hypomethylation and cyclic AMP provides a novel mechanism
for increased AR signaling in castration-recurrent prostate cancer.
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The androgen receptor (AR) mediates androgen-stimulated growth of benign prostate and
contributes to prostate cancer progression. Prostate cancers typically undergo remission during
androgen deprivation therapy, but recur with castration-recurrent growth and a poor prognosis
despite low circulating levels of testicular androgen. The CWR22 xenograft of human prostate
cancer mimics clinical prostate cancer with regression after castration. Castration-recurrent
growth of the CWR22 tumor begins ~120 days after castration to remove circulating testicular
androgens (1–3). AR functions in prostate cancer as a transcriptional regulator that drives
androgen-stimulated and castration-recurrent growth. Inhibition of prostate cancer growth by
reducing AR levels provides evidence that AR is a central mediator of prostate cancer
progression during androgen deprivation therapy, although the underlying mechanisms remain
to be established (4–8).
Prostate cancer cells utilize a number of mechanisms mediated through the AR to promote
tumor growth. One explanation for persistent AR activity in castration-recurrent cancer is the
local tissue production of active androgens, which provides a hormonal stimulus for AR
function (9,10). AR transcriptional activity is mediated through interactions with coregulator
proteins (11), and increased levels of critical coregulators, such as the SRC/p160 family of
coactivators, appear to contribute to prostate cancer growth and progression (12). In a few
instances, and more often in castration-recurrent prostate cancer, naturally occurring AR
somatic mutations promote androgen-stimulated prostate cancer growth. Gain-of-function AR
mutations can increase AR transcriptional activity by stabilizing interactions with SRC/p160
coactivators (13,14).
One recently identified AR coactivator is melanoma antigen gene protein-A11 (MAGE-11)
(15). MAGE-11 is a member of the MAGE-A subfamily of cancer-testis (or cancer-germline)
antigens (16) that is expressed in normal tissues of the human male and female reproductive
tracts, and in prostate cancer cells that express AR (15,17). MAGE-11 is expressed only by
human and nonhuman primates and is not present in the mouse or rat genomes, which suggests
that the MAGE gene family is undergoing rapid evolution (18,19). MAGE-11 increases AR
transcriptional activity by binding the AR NH2-terminal FXXLF motif through mechanisms
that include epidermal growth factor (EGF)-dependent phosphorylation and
monoubiquitinylation of MAGE-11 (20). The AR NH2-terminal FXXLF motif also mediates
the androgen-dependent AR N/C interaction with activation function 2 in the AR ligand binding
domain (21). AR binding to MAGE-11 relieves competitive inhibition of AR transcriptional
activity caused by the AR N/C interaction so that SRC/p160 coactivators are recruited more
freely by activation function 2 (22,23).
In the present study, MAGE-11 expression increased with time after castration as AR becomes
reactivated during prostate cancer progression in the CWR22 xenograft model of human
prostate cancer and in clinical prostate cancer specimens. In three different experimental
settings, which include prostate cell lines, CWR22 xenografts and clinical specimens of benign
and malignant prostate, increased expression of MAGE-11 resulted from hypomethylation of
CpG sites directly proximal to the MAGE-11 transcriptional start site. In studies using prostate
cancer cell lines, cyclic AMP (cAMP) signaling also increased MAGE-11 expression and AR
transcriptional activity, but did not alter DNA methylation of the MAGE-11 promoter. The
data suggest a mechanism whereby increased expression of MAGE-11 facilitates prostate
cancer progression by enhancing AR-dependent tumor growth.
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Increased MAGE-11 Expression during CWR22 Tumor Progression after Castration
Quantitative reverse transcription (RT)-PCR analysis of CWR22 tumor RNA obtained 2, 6 and
12 days after castration indicated increased levels of MAGE-11 mRNA in association with
tumor progression (Fig. 1A). Highest levels of MAGE-11 mRNA occurred on day 120 or longer
after castration when tumor growth recurred in the absence of circulating testicular androgens.
MAGE-11 immunostaining was nuclear and most prominent on day 6 and 12 after castration
(Fig. 2A). MAGE-11 protein levels also increased after castration when detected on
immunoblots, with highest levels in the castration-recurrent CWR22 tumor (Fig. 2B). CWR22
tumors are heterogeneous during remission after castration with regions undergoing massive
involution. Measurements of both MAGE-11 mRNA and protein indicated increased
expression of MAGE-11 in the CWR22 xenograft during progression to castration-recurrent
growth.
In parallel studies, AR mRNA levels also increased in the CWR22 tumor on day 2 after
castration and further at later times after castration in some samples (Fig. 1B). However, unlike
the striking increase in MAGE-11 mRNA in the castration-recurrent CWR22 tumor, AR
mRNA levels remained relatively constant after castration with few exceptions. On the other
hand, AR immunostaining (Fig. 2A) and immunoblotting (Fig. 2B) showed increased AR
protein in the castration-recurrent CWR22 tumor, as reported previously (24). AR coactivators
TIF2 and p300 mRNA levels were variable and did not correlate with tumor progression (Fig.
1C and D). Immunostaining (data not shown) and immunoblots (Fig. 2B) indicated relatively
constant levels of TIF2 and p300 during CWR22 tumor regression and regrowth, although
p300 declined in the castration-recurrent CWR22 tumor.
The data indicated that both MAGE-11 and AR mRNA and protein levels increase during
CWR22 tumor progression after castration. In the castration-recurrent CWR22 prostate cancer
xenograft, MAGE-11 mRNA increased to a greater extent in association with prominent
immunostaining of AR and MAGE-11.
MAGE-11 Expression in Clinical Specimens of Benign and Malignant Prostate
To investigate whether the increase in MAGE-11 during progression of the CWR22 xenograft
is a characteristic feature of prostate cancer progression, tissue specimens of benign, androgen-
stimulated and castration-recurrent prostate cancer were analyzed. MAGE-11 mRNA levels
were 10–1500 fold greater in 4 of 11 clinical specimens of castration-recurrent prostate cancer
than in androgen-stimulated benign prostate or prostate cancer (Fig. 3A). In one specimen, a
Gleason score of 4+5=9 castration-recurrent prostate cancer from patient-5 (CR-CaP-5)
obtained 49 months after the initiation of androgen deprivation therapy, MAGE-11 mRNA
levels increased by 1500 fold (Fig. 3A). A prostate-specific antigen serum level of 199 ng/dl
in CR-CaP-5 was indicative of AR signaling, even though AR mRNA was undetectable (Fig.
3B). AR mRNA levels also increased by 10–100 fold in 4 of 11 castration-recurrent prostate
cancer specimens. However, castration-recurrent prostate cancer specimens with increased
levels of AR mRNA had lower levels of MAGE-11 mRNA. In agreement with the results of
CR-CaP-5, the data suggest an inverse relationship between MAGE-11 and AR mRNA in
clinical specimens of castration-recurrent prostate cancer (Fig. 3C). MAGE-11 and AR protein
levels both increased in specimens of castration-recurrent prostate cancer (Fig. 3D).
The results indicated that ~30% of clinical specimens of castration-recurrent prostate cancer
have elevated levels of MAGE-11 or AR mRNA, which suggests the presence of a
compensatory relationship controlling AR transcriptional activity.
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MAGE-11 Promoter DNA Hypomethylation in the CWR22 Xenograft
The molecular basis for increased expression of MAGE-11 during prostate cancer progression
was investigated further based on evidence that DNA hypomethylation occurs for other cancer-
germline antigens (16,25). The MAGE-11 gene is located at Xq28 on the human X
chromosome (18) and contains a classical CpG island flanking the transcription start site (Fig.
4A). Pyrosequencing of 10 CpG sites ~200 bp before the transcription start site indicated 5%
DNA methylation of the MAGE-11 promoter in CWR22 xenografts excised from intact mice,
and on days 2, 6 and 12 after castration (Fig. 4B). In the CWR22 castration-recurrent tumor,
DNA methylation decreased further to 2%.
Methylation of individual CpG sites was investigated further using sodium bisulfite sequencing
of 20 CpG sites that included 10 additional downstream sites in closer proximity to the
transcription start site. Unmethylated (open circles) and methylated (filled circles) CpG sites
were determined for multiple alleles in CWR22 tumors on different days after castration (Fig.
4C). Hypomethylation at sites more distal to the transcription start site appeared to account for
the overall low percentage of DNA methylation in the CWR22 tumors, whereas CpG sites near
the transcription start site were methylated in intact CWR22 tumors and on day 2 after castration
(Fig. 4B and C). At later times after castration and in the castration-recurrent CWR22 tumor,
DNA methylation sites near the transcription start site were hypomethylated.
The results suggested that hypomethylation at CpG sites in direct proximity to the transcription
start site is associated with increased expression of MAGE-11 during CWR22 tumor
progression.
MAGE-11 Promoter DNA Hypomethylation in Clinical Specimens of Prostate Cancer
To extend this analysis to clinical specimens, pyrosequencing of the MAGE-11 promoter was
performed using benign and malignant prostate tissue to investigate further the dependence of
MAGE-11 expression on promoter DNA methylation during prostate cancer progression after
castration. Pyrosequencing analysis revealed that MAGE-11 methylation levels decreased in
castration-recurrent prostate cancer compared to androgen-stimulated benign prostate or
androgen-stimulated prostate cancer (Fig. 5A). In particular, the MAGE-11 methylation level
in CR-CaP-5, a castration-recurrent prostate cancer specimen that had 1500 fold higher
MAGE-11 mRNA levels than benign prostate (Fig. 3A), was reduced to 5% compared to ~70%
DNA methylation in androgen-stimulated benign prostate and androgen-stimulated prostate
cancer specimens (Fig. 5A). DNA hypomethylation of CR-CaP-5 was evident at all CpG sites
within the pyrosequenced region that was different than androgen-stimulated benign prostate
(AS-BP-3) and androgen-stimulated prostate cancer (AS-CaP-3) (Fig. 5B). The trend of
relative uniformity in methylation levels at individual CpG sites across the pyrosequenced
region was consistent across all samples analyzed (data not shown). Sodium bisulfite
sequencing of CR-CaP-5 indicated almost complete loss of DNA methylation, compared to
dense DNA methylation of the MAGE-11 promoter in androgen-stimulated benign prostate
(AS-BP-9) (Fig. 5C). CR-CaP-4 MAGE-11 mRNA levels were 1500 fold less than CR-CaP-5
(Fig. 3A) and dense methylation of CpG sites was retained in close proximity to the
transcription start site, although more distal CpG sites were hypomethylated (Fig. 5C, middle
panel).
The results from clinical specimens of benign prostate and prostate cancer provided further
evidence that DNA hypomethylation of CpG sites proximal to the MAGE-11 transcription start
site is correlated with increased expression of MAGE-11 in association with prostate cancer
progression to castration-recurrent growth.
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MAGE-11 Expression in Prostate Cancer Cell lines
The direct relationship between increased expression of MAGE-11 and promoter DNA
hypomethylation near the transcription start site, prompted a study of cell lines that express
AR and MAGE-11 at different levels. MAGE-11 mRNA levels were 10 to 100 fold higher in
LAPC-4 prostate cancer cells than in LNCaP, LNCaP-C4-2 or CWR-R1 prostate cancer cells,
each of which had high levels of AR mRNA (Fig. 6A). These results suggested a more direct
relationship between AR and MAGE-11 mRNA than was seen in clinical specimens of prostate
cancer. MAGE-11 mRNA levels were 10 to 1000 fold higher in LAPC-4, LNCaP, LNCaP-
C4-2 and CWR-R1 cells than in benign PWR-1E and RWPE-2 prostate cells, DU145 or PC-3
prostate cancer cells, or CV1 or COS-1 cells. In the majority of prostate cancer cell lines, AR
mRNA levels were 100 to 10,000 times higher than MAGE-11.
MAGE-11 protein expression determined using immunoblot analysis correlated with
MAGE-11 mRNA levels. Highest levels of MAGE-11 protein were in LAPC-4 cells, with
lowest levels in RWPE-2 and PWR-1E benign prostate cells (Fig. 6B). AR protein in CWR-
R1, CWR-RV1, LNCaP, LNCaP-C4-2 and LAPC-4 prostate cancer cell extracts (Fig. 6B)
correlated with AR mRNA levels (Fig. 6A). Under these assay conditions, AR protein was not
detected in PC-3 or DU145 prostate cancer cells, nor in PWR-1E and RWPE-2 benign human
prostate cells. Except for DU145 cells, in which AR mRNA was not detected, AR mRNA was
expressed in benign prostate cells (Fig. 6A), but at levels too low to detect on immunoblots
(Fig. 6B), and too low to activate androgen responsive genes in transient reporter gene assays
(data not shown).
As found in the CWR22 xenograft and tissue specimens of benign and malignant prostate,
MAGE-11 mRNA levels correlated directly with DNA methylation status of the MAGE-11
promoter in the majority of cell lines. Pyrosequencing of 10 CpG sites preceding the MAGE-11
transcription start site demonstrated 5% DNA methylation in LAPC-4 cells, which had the
highest levels of MAGE-11 mRNA and protein (Fig. 6 and Fig. 7A). MAGE-11 CpG site
methylation was 8 to 17% in LNCaP, LNCaP-C4-2 and CWR-R1 cells, 50 to 65% in DU145,
CV1 and COS cells, 35% in PWR-1E and RWPE-2, and 12% in PC-3 cells (Fig. 7A).
Representative examples of the extent of DNA methylation at the 10 individual CpG sites
interrogated by pyrosequencing are shown for LAPC-4 and DU145 cells (Fig. 7B).
Sodium bisulfite sequencing of the MAGE-11 promoter in LAPC-4, PC-3 and DU145 provided
further evidence that CpG site methylation at the transcription start site regulates MAGE-11
expression. Sodium bisulfite sequencing of CpG sites distal and proximal to the MAGE-11
transcription start site revealed extensive DNA hypomethylation in LAPC-4 cells that express
high levels of MAGE-11 (Fig. 7C, left panel). In contrast, CpG sites were densely methylated
in DU145 cells that express low levels of MAGE-11 (Fig. 7C, right panel). In PC-3 cells, which
show low expression of MAGE-11 (Fig. 6), the MAGE-11 promoter was hypomethylated at
CpG sites distal to the transcription start site, but hypermethylated at CpG sites proximal to
the transcription start site (Fig. 7C, middle panel). The results provided further evidence that
DNA methylation adjacent to the transcription start site may be sufficient to inhibit the
expression of MAGE-11.
To test directly whether DNA methylation of CpG sites proximal to the transcription start site
actively represses MAGE-11 expression, PC-3 and DU145 cells were treated with 5-aza-2´-
deoxycytidine, a DNA methyltransferase inhibitor, and MAGE-11 expression was assessed.
Treatment with 5-aza-2´-deoxycytidine increased MAGE-11 expression in both PC-3 and
DU145 cells (Fig. 7D), in association with hypomethylation of CpG sites proximal to the
transcription start site (Fig. 7E).
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Regulation of MAGE-11 Expression in Prostate Cancer Cell Lines by cyclic AMP
Regulation of MAGE-11 expression was investigated further based on evidence that cyclic
AMP (cAMP) increases, and 17β-estradiol decreases, MAGE-11 expression in human
endometrial cells (17). MAGE-11 mRNA levels increased up to 35 fold in a dose-dependent
manner in response to dibutyryl-cAMP in LNCaP-C4-2, CWR22-RV1, LAPC-4, LNCaP,
RWPE-2 and PWR-1E cells, as shown for LNCaP-C4-2 and PWR-1E cells (Fig. 8A and B).
The cAMP-dependent increase in MAGE-11 mRNA was evident within 12 h in LNCaP cells,
indicative of a transcriptional effect, was maximal by 24 h, and was not influenced by 17β-
estradiol (Fig. 8C).
In DU145 cells where the MAGE-11 promoter was densely methylated (Fig. 7C), MAGE-11
mRNA levels did not increase in response to cAMP relative to a 48 h control (Fig. 8D). The
inability of cAMP to increase MAGE-11 expression in DU145 cells suggests that extensive
promoter DNA methylation blocks cAMP signaling, and cAMP may not alter DNA
methylation of the MAGE-11 promoter. DNA methylation-dependent inhibition of cAMP
regulation was supported further by studies in CWR-RV1 and LNCaP-C4-2 cells, where the
extent of DNA methylation of the MAGE-11 promoter CpG sites determined by sodium
bisulfite sequencing, was unchanged after 48 h treatment with 8 mM dibutyryl-cAMP (data
not shown). Furthermore, cAMP did not increase MAGE-11 mRNA levels in DU145 cells
after treatment with the DNA methyltransferase inhibitor, 5-aza-2´-deoxycytidine, although a
small potentiation effect was apparent in PC-3 cells (data not shown).
The results suggested that hypomethylation within the MAGE-11 promoter near the
transcription start site is necessary but not sufficient for cAMP-dependent up-regulation of
MAGE-11.
cAMP Regulation of AR Transcriptional Activity
To determine whether the cAMP-dependent increase in MAGE-11 is associated with an
increase in AR transcriptional activity, AR and a prostate-specific antigen-luciferase reporter
gene were coexpressed in LNCaPC4-2 and DU145 prostate cancer cells, two cell lines that
differ in the extent of MAGE-11 promoter DNA methylation, expression and responsiveness
to cAMP. AR transactivation increased up to 25 fold in response to dibutyryl-cAMP in a dose-
dependent manner in LNCaP-C4-2 cells in the absence and presence of 1 nM DHT (Fig. 9A).
In contrast, increased AR transactivation in DU145 cells required higher concentrations of
cAMP and was evident only in the presence of DHT (Fig. 9B).
The results suggested that increased AR transcriptional activity in response to cAMP results
at least in part from increased expression of MAGE-11. To test this further, MAGE-11 siRNA
was used to reduce expression in CWR-R1 prostate cancer cells, where endogenous AR
transcriptional activity can be measured using an MMTV-luciferase reporter vector. The
cAMP-dependent increase in AR transcriptional activity was retained in CWR-R1 cells treated
with MAGE-11 siRNA-3, which does not alter MAGE-11 expression, but was lost after
treatment with MAGE-11 siRNA-2, which reduces MAGE-11 expression (20) (Fig. 9C).
The results raised the possibility that the cAMP-dependent increase in AR transcriptional
activity occurs through mechanisms that include increased expression of MAGE-11. On the
other hand, the ability of higher concentrations cAMP to increase AR transcriptional activity
in DU145 cells provideed evidence that additional cAMP-dependent mechanisms increase AR
transcriptional activity possibly independent of MAGE-11.
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MAGE-11 Expression during Prostate Cancer Progression
This report provides evidence that increased expression of the AR selective coregulator
MAGE-11 represents a novel mechanism to promote AR-dependent growth of prostate cancer.
In three experimental settings, MAGE-11 expression increased in prostate cancer as a result
of MAGE-11 promoter DNA hypomethylation at the transcription start site or in response to
cAMP. In clinical specimens of castration-recurrent prostate cancer, the MAGE-11 promoter
region was hypomethylated, and correlated with increased expression of MAGE-11.
MAGE-11 mRNA levels were highest in clinical specimens of castration-recurrent prostate
cancer, where CpG sites were hypomethylated directly proximal to the transcription start site.
In the CWR22 xenograft model of human prostate cancer, the MAGE-11 gene was
hypomethylated in the androgen-stimulated tumor prior to castration, which suggests that the
androgen-stimulated CWR22 tumor model represents an advanced stage of the disease.
However, with progression to castration-recurrent growth, MAGE-11 expression increased
~100 fold in the CWR22 xenograft, and correlated with hypomethylation at CpG sites proximal
to the transcription start site of the MAGE-11 promoter. MAGE-11 expression levels in cell
lines similarly correlated with promoter DNA methylation proximal to the transcription start
site, and hypomethylation was associated with increased expression. The ability of DNA
methylation to inhibit MAGE-11 expression was especially evident among the prostate cancer
cell lines. Most striking was the DU145 cell line, where MAGE-11 expression was low and
the promoter was densely methylated.
While the predominant mechanism for increased expression of MAGE-11 during prostate
cancer progression to castration-recurrent growth appears to be hypomethylation at the
transcription start site, MAGE-11 gene expression was also up-regulated by cAMP. cAMP
increased MAGE-11 expression in prostate cancer cells that were hypomethylated more
extensively in the MAGE-11 promoter region that appeared to be independent of a change in
DNA methylation. In contrast, the lack of cAMP stimulation of MAGE-11 expression in
DU145 cells suggested that cAMP does not override the inhibitory effects of an extensively
methylated MAGE-11 promoter. The results suggest that basal expression of MAGE-11 is
blocked by DNA methylation near the transcription start site, some extent of hypomethylation
in the MAGE-11 distal promoter is required for up-regulation by cAMP, and additional cell
specific factors likely contribute MAGE-11 gene regulation by cAMP. MAGE-11 promoter
DNA in clinical specimens of benign prostate tissue was methylated extensively, but only
methylated partially in the PWR-1E and RWPE-2 cell lines that derive from benign prostate.
These findings make it difficult to predict whether MAGE-11 expression is sensitive to cAMP
stimulation in benign prostate tissue under normal physiological conditions.
The cAMP-dependent increase in AR transcriptional activity appears to result in part to an
increase in the expression of MAGE-11. Depletion of MAGE-11 levels in CWR-R1 cells using
siRNA that inhibits MAGE-11 expression, inhibited the cAMP-dependent increase in AR
transcriptional activity. However, cAMP also increased AR transcriptional activity when AR
was expressed in DU145 cells, a cell line that lacks endogenous AR and MAGE-11, and where
MAGE-11 mRNA levels were not increased by cAMP. AR transcriptional activity was
increased by cAMP in LNCaP-C4-2 cells in the absence and presence of androgen, which may
reflect the increased expression of MAGE-11. The data suggest that additional mechanisms,
possibly involving other coregulatory proteins (26), contribute to the cAMP-dependent
increase in AR transcriptional activity.
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Relationship between AR and MAGE-11
AR transcriptional activity is increased through several mechanisms involving MAGE-11.
Through its interaction with the AR NH2-terminal FXXLF motif, MAGE-11 increases AR
recruitment of SRC/p160 coactivators by activation function 2 in the AR ligand binding domain
and inhibition of the AR N/C interaction (15). The effects of MAGE-11 on AR transcriptional
activity are enhanced by EGF signaling, and MAGE-11 stabilizes AR in the absence or at low
levels of androgen (15,17,20). The stabilizing effect of MAGE-11 on AR under conditions of
low androgen raises the possibility that increases in MAGE-11 in the CWR22 tumor on days
6 and 12 after castration, and in the castration-recurrent tumor, provides a mechanism to
increase AR levels in the low androgen environment in the absence of the stabilizing effects
of the androgen-dependent AR N/C interaction. AR stabilization by MAGE-11 in castration-
recurrent prostate cancer may contribute to the apparent increase in AR protein when AR
mRNA levels remained relatively constant after castration. Greater levels of AR could increase
the sensitivity to low circulating androgen levels associated with androgen deprivation therapy
in the treatment of prostate cancer. Increased levels of MAGE-11 may also increase ligand-
independent AR transactivation, as suggested by studies using the LNCaP-C4-2 prostate cancer
cell line.
The apparent inverse relationship between AR and MAGE-11 mRNA levels identified in
clinical specimens of castration-recurrent prostate cancer suggests a compensatory relationship
between AR and MAGE-11 at the level of gene regulation. This relationship also was seen in
some samples of the CWR22 xenograft, but not in the prostate cancer cell lines. Present
evidence indicates that MAGE-11 expression is not regulated by androgen (data not shown),
and increased expression of MAGE-11 is associated with prostate cancer progression to
recurrent growth. Hypomethylation and cAMP signaling may account for the increased
expression of MAGE-11 during prostate cancer progression, and contribute to AR-mediated
castration-recurrent growth of prostate cancer. The molecular basis for the difference in relative
levels of AR and MAGE-11 mRNA between castration-recurrent tumor specimens and prostate
cancer cell lines remains to be established.
Epigenetic Regulation of MAGE-11
Increased DNA hypomethylation at CpG sites in the MAGE-11 promoter and the associated
increase in MAGE-11 expression was greatest in castration-recurrent prostate cancer in the
CWR xenograft model and clinical specimens of prostate cancer. Epigenetic abnormalities in
gene silencing and activation observed for MAGE-11 are now well established markers for
cancer development (27). These results demonstrate that hypomethylation of specific CpG sites
proximal to the transcription start site is most critical in regulating MAGE- 11 expression,
whereas more distal hypomethylation may influence regulation by cAMP. The lack of a cAMP-
dependent increase in MAGE-11 associated with the densely methylated 5´ CpG island in
DU145 cells suggests that MAGE-11 promoter DNA hypomethylation distal to the
transcription start site is required for cAMP stimulation of MAGE-11 expression. On the other
hand, recent genome-wide studies on DNA methylation, histone modification patterns and
gene expression, support the importance of epigenetic marks proximal to the transcription start
site in gene regulation (28,29). Localized DNA hypomethylation may alter chromatin structure
at the MAGE-11 transcription start site even when flanking DNA is hypermethylated.
Cancer cells exhibit global decreases in 5-methylcytosine and DNA hypomethylation to
various extents depending on tumor stage and type, which may contribute to chromosomal
instability and acquisition of mutations (30,31). Growth promoting genes can be activated by
DNA hypomethylation in tumors (32). Although relatively little is known about the
mechanisms of genome-wide or gene-specific DNA hypomethylation, recent evidence
suggests that the expression of DNA methyltransferase 3b (DNMT-3b) isoforms or aberrant
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expression of the BORIS/CTCFL imprinting-related protein plays a role (33,34). Germline-
specific genes, such as MAGE-11 and other members of the MAGE family, become methylated
during normal development (35) and some members of the family of cancer-germline genes
undergo DNA hypomethylation in cancer (16,30). Germline antigen gene activation in cancer
has led to the development of cancer vaccines targeting these antigens (16). DNA
hypomethylation at CpG sites in the MAGE-11 promoter associated with the onset of
castration-recurrent prostate cancer may have critical consequences to tumor growth based on
the ability of MAGE-11 to increase AR transcriptional activity in the presence and especially
in the relative absence of androgen. The AR coregulator MAGE-11 may be a viable therapeutic
and/or vaccine target in some cases of castration-recurrent prostate cancer.
MATERIALS AND METHODS
Clinical Prostate and CWR22 Xenograft Sample Preparation
Serially transplanted androgen-dependent and nonmetastatic CWR22 human prostate cancer
xenografts derived from a primary human prostate cancer were propagated in athymic nu/nu
mice (24,36). Some animals were castrated and testosterone pellets removed after tumors
reached ~0.75 g. CWR22 tumors from intact mice and on days 2, 6, 12 and 120 or longer after
castration when castration-recurrent tumors develop, were formalin-fixed and paraffin-
embedded for immunocytochemistry or frozen for DNA and RNA extraction. Patient
specimens of androgen-stimulated benign prostate were obtained by radical prostatectomy
from African and Caucasian Americans aged 47 to 72 years. Clinically localized androgen-
stimulated prostate cancer was obtained from radical prostatectomy specimens from African
and Caucasian Americans 44 to 62 years of age, and castration-recurrent prostate cancer
(Gleason score 3+5=8 to 5+5=10) was obtained from transurethral resection specimens from
men aged 61 to 86 years who suffered urinary retention from local recurrence. Prostatectomy
specimens were macrodissected (37) to enrich for benign or malignant epithelial cells when
their content was < 80%. This method resulted in an average of 92% malignant epithelial cells
in androgen-stimulated prostate cancer specimens (9). Tissues were stored in liquid nitrogen
or formalin-fixed and paraffin-embedded for immunocytochemistry. Animal procedures and
patient sample collections were performed in accordance with institutional guidelines.
Cell Culture
Cells were maintained in media containing phenol red, penicillin (100 U/ml), streptomycin
(100 µg/ml) and 2 mM L-glutamine. LNCaP prostate cancer cells were maintained in
RPMI-1640 (Cellgro) containing 1 mM sodium pyruvate and 10% fetal bovine serum (FBS,
Sigma). LNCaP-C4-2 prostate cancer cells were cultured in Dulbecco’s modified Eagle
medium (DMEM)-F12 containing 5% FBS, 5 µg/ml insulin, 13.65 pg/ml triiodothyronine, 5
µg/ml apotransferrin, 0.244 µg/ml d-biotin and 25 µg/ml adenine hemisulfate (Sigma).
CWRR1 cells derived from the castration-recurrent CWR22 prostate cancer xenograft (12)
were maintained in DMEM with high glucose, 5 µl 90 mg/ml linoleic acid (Sigma), 0.6 g
nicotinamide (Sigma), 0.5 ml insulin-transferin-selenium mix (Roche), 10 ml FBS and 10 ng/
ml EGF in 500 ml medium. Serum-free CWR-R1 cell medium was Improved Zinc Optimal
with additives without serum, phenol red and EGF. CWR22-RV1 cells derived from the
CWR22 human prostate xenograft (American Type Culture Collection) were maintained in
RPMI-1640 medium (Cellgro) containing 10% FBS, 1 mM sodium pyruvate, 4.5 g/L glucose,
1.5 g/L sodium bicarbonate and 10 mM Hepes, pH 7.2. LAPC-4 prostate cancer cells were
grown in RPMI-1640 with 10% FBS and 1 nM methyltrienolone. PC-3 cells were cultured in
DMEM-F12 with 10% FBS. DU145 cells were propagated in Eagle’s Minimum Essential
Medium with 10% FBS. Benign human prostate PWR-1E and RWPE-2 cells were maintained
in keratinocyte serum-free and phenol red-free medium containing 2.5 µg human recombinant
EGF and 25 mg bovine pituitary extract per 500 ml. HeLa human cervical cancer cells were
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maintained in Eagle’s Minimum Essential Medium with 10% FBS. Ishikawa human
endometrial cancer cells were propagated in Minimum Essential Medium with 10% FBS.
Monkey kidney CV1 and COS-1 cells were cultured in DMEM with high glucose, 20 mM
Hepes, pH 7.2 and 10% bovine calf serum (Hyclone).
Cells cultured in serum-free or 5% charcoal-stripped serum (Atlanta Biologicals) medium were
treated with and without dibutyryl-cAMP (Sigma). Reporter gene assays were performed using
Effectene (Qiagen) or FuGENE-6 Transfection Reagent (Roche Applied Science) with pCMV-
AR and prostate-specific antigen-enhancer luciferase vector, PSA-Enh-Luc (14). Cells were
transferred to phenol red-free, serum-free or 5% charcoal-stripped serum medium, and
incubated 24 h with and without DHT or dibutyryl-cAMP and assayed for luciferase activity
(14).
Real-time Reverse Transcription PCR
CWR22 tumors (50 to 150 mg) and cultured cells were extracted using TRIzol Reagent
(Invitrogen). Tumors were disrupted using a Brinkmann polytron (Switzerland). RNA from
patient samples was obtained by extracting 0.1 ml AllPrep DNA/RNA extraction kit lysate
(Qiagen) with 3 ml TRIzol. First strand cDNA was prepared using SuperScript II reverse
transcriptase (Invitrogen). PCR primers and fluorogenic probes for peptidylprolyl isomerase
A (PPIA, cyclophilin A) and human AR and MAGE-11 were described (17), however sequence
homology for African green monkey COS and CV1 cells could not be confirmed. Primers and
probes for transcriptional intermediary factor 2 (TIF2) (Hs00197990-m1) from Assays-On-
Demand (Applied Biosytems, 99 bp amplicon) span the exon 14–15 junction at 3193
(NM006540.2). p300 primers and probes (Hs00914232-m1, Applied Biosytems, 138 base pair
amplicon) span the exon 9-10 junction at assay location 2279 (NM001429.2). PCR reactions
(20 µl) contained complementary DNA from 0.4 µg total RNA for AR, TIF2, MAGE-11 and
PPIA, or 0.04 µg total RNA for p300 and PPIA, 4 µl Light Cycler TaqMan Master mix (Roche)
and 0.5 µl 20X TaqMan Mix (Applied Biosystems). Thermal cycler reactions were performed
at 95°C for 10 min, 55 cycles at 95°C for 15 s, 60°C for 25 s and 72°C for 1 s. Standard curves
were prepared as described (17).
Immunochemistry
Immunocytochemistry was performed on formalin-fixed, paraffin-embedded sections of
CWR22 prostate cancer xenograft and clinical specimens of androgen-stimulated benign
prostate, androgen-stimulated prostate cancer, and castration-recurrent prostate cancer (17).
MAGE-11 antibody MagAb94-108 (8 µg/ml) recognizes amino acid residues 94–108 (17).
Human p300 C-20 antibody was obtained from Santa Cruz (sc-585, 1:100 dilution). Tissue
sections were treated with 0.01 M sodium citrate, pH 6.0, for 15 min in a microwave at high
setting (38) to retrieve antigens for affinity purified rabbit polyclonal PG21 AR antibody
(Upstate, 1:150 dilution) and mouse monoclonal human TIF2 IgG1 antibody (BD Transduction
Laboratories, 1:300 dilution), Sections were blocked with 2% goat serum, incubated overnight
at 4°C with primary antibody, blocked and incubated for 30 min with biotinylated secondary
antibody (Vector Labs). For MAGE-11 immunostaining, CWR-22 tumor sections were
incubated for 30 min with biotinylated secondary antibody and 30 min with avidin DH-
biotinylated horseradish peroxidase H complex Vectastain Elite ABC kit (Vector Labs). For
AR, TIF2 and p300, samples were incubated for 1 h with biotinylated secondary antibody, and
1 h with avidin DH-biotinylated horseradish peroxidase H complex Vectastain Standard ABC
kit (Vector Labs). Benign prostate and prostate cancer slides were incubated using the
Vectastain Standard ABC kit for MAGE-11 and AR. Slides were immersed in 3,3’-
diaminobenzidine tetrahydrochloride (17), exposed to osmium vapors and counterstained with
0.05% toluidine blue in 30% ethanol, dehydrated, cleared in xylene and mounted with
Permount (Fisher).
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For immunoblots, cells were solubilized in 0.3–0.4 ml 1% Triton X-100, 1% deoxycholate,
0.1% SDS, 0.15 M NaCl, 0.5 mM EDTA, 50 mM NaF, 0.5 mM Na3VO4 and 50 mM Tris-
HCl, pH 7.4, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 5 µg/ml leupeptin, 5
µg/ml pepstatin A and 5 µg/ml aprotinin, and sedimented at 4°C for 30 min at 20,000×g.
Extracts from 0.1–0.2 g CWR22 tumor were lysed in 2 ml buffer with detergents added after
homogenization using a Brinkmann polytron. Tissue extracts were sedimented at 4°C for 1 h
at 27,000 rpm in a Ti60 Beckman ultracentrifuge rotor. Protein controls were from COS cells
transfected with pSG5- MAGE-11 (15,17), pCMVhAR (39), pSG5-TIF2 and pSG5-HA-p300.
Protein concentration was determined using the BioRad assay and bovine serum albumin as
standard.
Protein extracts from cells (50 µg) and tissues (100 µg) were separated on 10% acrylamide
gels containing SDS. Nitrocellulose transfer blots (PerkinElmer) were probed with MAGE-11
antibodies MagAb94-108, MagAb59-79 and MagAb13–26 (10 µg/ml each) (17), AR32 rabbit
polyclonal antipeptide antibody (2 µg/ml), mouse monoclonal TIF2 IgG1 antibody (BD
Transduction Laboratories, 1:250 dilution), rabbit polyclonal p300 C-20 antibody (Santa Cruz
sc-585, 1:800 dilution) and mouse monoclonal β-actin antibody (Abcam, 1:5000). Blots were
incubated with primary antibody overnight at 4°C and with anti-rabbit or anti-mouse
horseradish peroxidase-conjugated secondary IgG antibody (1:10,000 dilution, Amersham
Biosciences) for 1 h at room temperature, and except MAGE-11 antibody, the secondary
antibody was incubated at 4°C for 1 h. Signals were detected using chemiluminescence
(SuperSignal West Dura Extended Duration Substrate, Pierce).
DNA Methylation Analyses
The 5´ end of MAGE-A11 transcript variant 1 (NCBI accession #NM-005366) contains a CpG
island (500 bp, GC = 59.4%, CpG obs/exp = 0.6) as predicted by
uscnorris.com/cpgislands2/cpg.aspx. Sodium bisulfite sequencing was performed as described
(25) using genomic DNA from tissue samples (50 to 150 mg) extracted using the AllPrep DNA/
RNA extraction kit (Qiagen). Frozen tissue was homogenized in RLT lysis buffer using a
polytron. Extracts were centrifuged at 12,000×g for 3 min and stored at −80°C. Genomic DNA
was sodium bisulfite converted using the EZ DNA methylation kit (Zymo Research, Orange,
CA). Primers for amplification of the MAGE-11 CpG island were -219 forward 5´-
GGAGGATTGAGGTATTTTTATG AT-3´ and +47 reverse 5´-CACTCTCAAAACA
CCCCTCAAAA-3´. Sodium bisulfite pyrosequencing was performed as described (40) using
MAGE-A11 forward PCR primer -219 5´-GGAGGATTGAGGTATTTTTA TGAT-3´,
MAGE-A11 reverse PCR primer −70 5´-biotin-AAACTT CCCTAAATTTACAACAAA-3´
and MAGE-A11 sequencing primer -212 5´-TTGAGGTATT TTTATGATTT-3´. PCR cycling
conditions were 95°C for 30 sec, 59°C for 30 sec and 72°C for 1 min for 45 cycles.
Pyrosequencing was performed on duplicate samples repeated at least twice. Human genomic
DNA modified with bacterial CpG methylase SssI (New England Biolabs, Beverly, MA)
served as positive control for DNA methylation. Genomic DNA from DNMT1−/−, DNMT3b
−/− HCT116 colorectal cancer cells was used as a negative DNA methylation control (41).
Cell Treatments with 5-aza-2´-deoxycytidine
PC-3 and DU145 cells were treated with 0, 0.1, 0.5 and 1.0 µM 5-aza-2´-deoxycytidine (Sigma)
in phosphate buffered saline at 0 and 48 h. RNA was harvested 120 h (5 days) post-treatment
and analyzed for MAGE-11 using reverse transcription PCR (15).
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Figure 1. Increase in MAGE-11 mRNA during CWR22 prostate cancer progression relative to AR,
TIF2 and p300
(A) MAGE-11, (B) AR, (C) TIF2 and (D) p300 mRNA levels were determined relative to
peptidylprolyl isomerase A (PPIA) using quantitative RT-PCR of CWR22 xenografts excised
from 6 animals per group of intact nude mice (0 day) and on days 2, 6, 12 and 120 or longer
after castration. Castration-recurrent tumors obtained 120 days or longer after castration were
characterized by growth in the absence of circulating testicular androgens.
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Figure 2. Increase in MAGE-11 protein during CWR22 prostate cancer progression
(A) MAGE-11 and AR immunostaining was analyzed in formalin-fixed, paraffin-embedded
sections of the CWR22 xenograft excised from intact non-castrated mice, and on days 2, 6, 12
and 120 after castration and longer for the castration-recurrent tumor, using MAGE-11
antibody MagAb94-108 (8 µg/ml) and AR PG21 (Upstate, 1:150 dilution). Brown reaction
product indicates immunoreactivity against a toluidine blue counterstain. Original
magnification 400X. (B) Immunoblots of MAGE-11, AR, TIF2 and p300 were assayed using
CWR22 xenograft extracts prepared from intact-7 (day 0, lane 2), day 2 castrate-3 (lane 3),
day 6 castrate-2 (lane 4), day 12 castrate-2 (lane 5), day 120 castrate-3 (lane 6) and castration-
recurrent-4 (Rec), according to the numbering of RNA analysis in Fig. 1. Protein extracts (100
µg/lane) were analyzed using antibodies as described in Methods. Combined extracts from
COS cells transfected with pSG5-MAGE-11, pCMV-AR, pSG5-TIF and pSG5-HA-p300
served as protein controls (lanes 1 and 8) and endogenous β-actin served as a loading control.
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Figure 3. MAGE-11 and AR expression in clinical specimens of benign and malignant prostate
(A) MAGE- 11 and (B) AR mRNA levels relative to peptidylprolyl isomerase A (PPIA) are
shown on a semi-log plot determined using quantitative RT-PCR from clinical specimens of
androgen-stimulated benign prostate (AS-BP), androgen-stimulated prostate cancer (AS-CaP),
and castration-recurrent prostate cancer (CR-CaP). (C) Inverse relationship between AR and
MAGE-11 mRNA levels in patient specimens of castration-recurrent prostate cancer. AR and
MAGE-11 mRNA levels were determined in duplicate using quantitative PCR of RNA
extracted from castration-recurrent prostate cancer specimens. Each of the duplicate data points
from the analysis of castration-recurrent specimens in Fig. 2A and B were used to construct
the graph. Correlation coefficient R2 = 0.66. (D) MAGE-11 and AR immunostaining of benign
and malignant human prostate tissue was performed using formalin-fixed, paraffin-embedded
sections of androgen-stimulated benign prostate (AS-BP), androgen-stimulated prostate cancer
(AS-CaP), and castration-recurrent prostate cancer (CR-CaP), using MAGE-11 antibody
MagAb94-108 (8 µg/ml) and AR antibody PG21 (1:150 dilution). Original magnification
400X.
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Figure 4. DNA hypomethylation of the MAGE-11 promoter during CWR22 prostate cancer
xenograft progression
(A) The MAGE-A11 5´ promoter region and CpG island as predicted using
http://www.uscnorris.com/cpgislands2/cpg.aspx in the range 148575477 to 148605507 on the
reverse complement strand (Accession # NC-000023) are shown. CpG island characteristics
are indicated. CpG sites in the 5´ CpG island of MAGE-11 (−367 to +133 relative to the
transcription start site) are indicated by black vertical lines, and CpG sites analyzed using
pyrosequencing by red vertical lines. Regions analyzed using sodium bisulfite pyrosequencing
and standard sodium bisulfite sequencing, and the number of CpG sites analyzed using each
method are indicated. (B) Sodium bisulfite pyrosequencing of MAGE-11 promoter DNA
methylation in CWR22 xenografts before and after castration. Shown is the percent DNA
methylation averaged over 10 analyzed CpG sites in the MAGE-11 promoter region indicated
in red in (A). Human genomic DNA modified with bacterial CpG methylase SssI and DNMT-
deficient HCT116 colorectal cancer cell DNA (DKO) served as positive and negative controls
for MAGE-11 5´ region DNA methylation, respectively. Each bar represents the average ± SE
of four independent pyrosequencing analyses. (C) Sodium bisulfite sequencing of the
MAGE-11 promoter DNA methylation in CWR22 xenografts before and after castration.
Tumors were analyzed from intact mice (intact-5) and on day 2 after castration (day 2
castrate-3), day 6 after castration (day 6 castrate-2), day 12 after castration (day 12 castrate-6)
and during castration-recurrent tumor growth more than 120 days after castration (recurrent-1
and recurrent-5), with samples designations according to Fig. 1. Open circles indicate
unmethylated CpG sites, filled circles are methylated CpG sites, and rows are individually
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sequenced alleles. The transcription start site is shown by the right arrow and the region
analyzed using pyrosequencing in (B) is indicated by brackets.
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Figure 5. DNA hypomethylation of the MAGE-11 promoter region in clinical specimens of benign
and malignant prostate
(A) Sodium bisulfite pyrosequencing analysis of MAGE-11 promoter DNA methylation in
androgen-stimulated benign prostate (AS-BP), androgen-stimulated prostate cancer (AS-CaP),
and castration-recurrent prostate cancer (CR-CaP) specimens. Shown is the percent DNA
methylation averaged over 10 CpG sites in the MAGE-11 promoter region indicated in red in
Fig. 4A. Human genomic DNA modified with bacterial CpG methylase SssI and DNMT-
deficient HCT116 colorectal cancer cells DNA (DKO) served as positive and negative controls
for MAGE-11 5´ region DNA methylation, respectively. Each bar represents the average ± SE
of four independent pyrosequencing analyses. (B) DNA methylation at individual CpG sites
in the MAGE-11 promoter region determined using pyrosequencing. Representative examples
of AS-BP-3, AS-CaP-3 and CRCaP- 5 are shown. CpG sites are numbered 1–10 starting at the
5´ site (nucleotide position -192 relative to the transcription start site). Each bar represents the
average ± SE of four independent pyrosequencing analyses. (C) Sodium bisulfite sequencing
of the MAGE-11 promoter in human specimens of androgen-stimulated benign prostate and
castration-recurrent prostate cancer. Samples include AS-BP-9, CR-CaP-4 and CR-CaP-5, and
are designated according to Fig. 2. Open and filled circles indicate unmethylated and
methylated CpG sites, respectively, and rows indicate individually sequenced alleles.
Methylation status of CpG sites shown with hashed lines could not be determined accurately.
The transcription start site is shown by the right arrow and the region analyzed using
pyrosequencing in (A) and (B) is indicated by brackets.
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Figure 6. MAGE-11 expression in benign and malignant cell lines
(A) MAGE-11 and AR mRNA levels were determined using quantitative PCR for human
prostate cancer cell lines LNCaP (LN), LNCaP-C4-2 (C4), CWRR1 (CW), CWR22-RV1 (RV),
LAPC-4 (LA), PC-3 (PC), DU145 (DU), benign human prostate cell lines PWR- 1E (PW) and
RWPE-2 (RW), human cervical carcinoma HeLa (HL), human endometrial cancer Ishikawa
(IS), monkey kidney CV1 (CV) and COS-1 cells (CO). mRNA amounts were normalized to 1
µg total RNA. (B) Immunoblot of MAGE-11 and AR is shown for extracts (50 µg protein/
lane) of CWR-R1 (lane 2), CWR22-RV1 (lane 3), LNCaP (lane 4), LNCaP-C4-2 (lane 5), PC-3
(lane 6), DU145 (lane 7), LAPC-4 (lane 8), RWPE-2 (lane 9) and PWR-1E (lane 10), with
abbreviations as in (A). Cells were cultured in serum containing media and analyzed on a 10%
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acrylamide gel containing SDS. The blot was probed using AR32 (2 µg/lane, top panel) and
combined MAGE-11 antibodies 94–108, 59–79 and 13–26 (10 µg/ml each, bottom panel).
Combined extracts of COS cells transfected with pSG5-MAGE-11 and pCMV-AR (lanes 1
and 11) were included as controls.
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Figure 7. MAGE-11 promoter DNA methylation status in benign and malignant cell lines
(A) Sodium bisulfite pyrosequencing of MAGE-11 promoter DNA methylation in human and
monkey benign and malignant cell lines. Shown is percent DNA methylation averaged over
10 CpG sites in the MAGE-11 promoter region indicated in red in Fig. 4A for human prostate
cancer cell lines LNCaP, CWR-R1, LAPC-4, LNCaP-C4-2, PC-3, DU145, benign human
prostate cell lines PWR-1E and RWPE-2, human endometrial cancer Ishikawa, monkey kidney
CV1 and COS-1, and human cervical cancer HeLa cells. Human genomic DNA modified with
bacterial CpG methylase SssI and DNMT-deficient HCT116 colorectal cancer cells DNA
(DKO) served as positive and negative controls for MAGE-11 5´ region DNA methylation,
respectively. Each bar represents the average ± SE of four independent pyrosequencing
analyses. (B) DNA methylation at individual CpG sites in the MAGE-11 promoter region in
LAPC-4 and DU145 cells determined using pyrosequencing. CpG sites are numbered 1–10
starting at the 5´ site (nucleotide position −192 relative to the transcription start site). Each bar
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represents the average ± SE of four independent pyrosequencing analyses. (C) Sodium bisulfite
sequencing of the MAGE-11 promoter in LAPC-4, PC-3 and DU145 cells. Open and filled
circles indicate unmethylated and methylated CpG sites, respectively, and rows indicate
sequenced alleles. The transcription start site is shown by the right arrow and the region
analyzed using pyrosequencing in (A) and (B) is indicated by brackets. The percent methylation
of three CpG sites proximal to the transcriptional start site is indicated and takes into account
all sequenced alleles for each sample. (D) Activation of MAGE-11 expression by DNA
demethylation using 5-aza-2´-deoxycytidine (DAC). PC-3 and DU145 cells were treated at 0
and 48 h with 0, 0.1, 0.5 and 1 µM DAC in phosphate buffered saline and RNA was harvested
for analysis at 120 h (5 days post treatment). MAGE-11 expression levels were determined
using RT-PCR of total RNA extracted with Trizol. RT-PCR amplification of glyceraldehyde
3- phosphate dehydrogenase (GAPDH) served as control for cDNA input. Neg indicates a no
template control reaction. (E) Sodium bisulfite sequencing of the MAGE-11 promoter in PC-3
(left panel) and DU145 cells (right panel) following 0.5 µM DAC five days post treatment.
Open and filled circles indicate unmethylated and methylated CpG sites, respectively, and rows
indicate sequenced alleles. The transcription start site is shown by the right arrow. The percent
methylation of three CpG sites proximal to the transcriptional start site is indicated and takes
into account all sequenced alleles for each sample.
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Figure 8. Cyclic-AMP-dependent increase in MAGE-11 expression
Dose-dependent increases in MAGE-11 mRNA levels in response to cAMP were measured in
(A) LNCaP-C4-2, (B) PWR-1E cells, (C) LNCaP, and (D) DU145 cells, at the indicated times
after treatment in 5% charcoal-stripped serum in the absence and presence of 0.5, 2 and 8 mM
dibutyryl-cyclic AMP (db-cAMP). In (C), LNCaP cells were treated in the absence and
presence of 7.5 mM db-cAMP for 0, 6, 12, 24 and 48 h, and for 48 h with 10 nM 17β-estradiol
in the absence and presence of 7.5 mM db-cAMP. Total RNA was extracted and MAGE-11
mRNA levels were determined using RT-PCR. The data are representative of two independent
experiments.
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Figure 9. Effects of cyclic-AMP on AR transcriptional activity
Dose-dependence of androgen-dependent and androgen-independent AR transcriptional
activity in response to cAMP was measured in (A) LNCaP-C4-2, and (B) DU145 prostate
cancer cells. Cells were transfected in 12 well plates using Effectene (Qiagen) with 10 ng/well
pSG5 (p5) empty vector or 10 ng/well pCMV-AR with 0.25 µg/well PSA-Enh-Luc in 5%
charcoal-stripped serum medium. Cells were treated for 24 h in 5% charcoal-stripped serum
containing media in the absence and presence of 1 nM DHT and 0, 0.5, 2 and 8 mM db-cAMP
as indicated. Luciferase activity is representative of three independent experiments. (C)
Inhibition of cAMP-stimulated endogenous AR transcriptional activity in CWR-R1 cells using
MAGE-11 siRNA. CWR-R1 cells (1.6 × 105/well in 12 well plates) were plated in serum
containing growth medium and transferred the next day into antibiotic-free medium containing
5% charcoal-stripped serum. Cells were transfected using Lipofectamine-2000 Reagent
(Invitrogen) with 0.1 µg MMTVΔ-421–-364-Luc/well (an MMTV-Luc reporter with deletion
of a negative response element) in the presence of 2 nM MAGE-11 siRNA-3, which does not
inhibit MAGE-11 expression, and 2 nM MAGE-11 siRNA-2, which reduces MAGE-11
expression (20). Cells were placed the next day in serum-free, phenol red-free medium, and
24 h later the medium was replaced with serum-free medium with and without 0.1 nM DHT
and 0.5 mM dibutyryl-cAMP (db-cAMP). Cells were cultured for 24 h and luciferase activity
was measured. The results are representative of four independent experiments.
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